Free Evaluation
Roundup
Cancer Lawsuit
Let’s talk about your story.
Fill out this form for a FREE CASE EVALUATION from one of our award-winning attorneys.
After you submit your information, one of our representatives will call you to discuss your claim. By submitting our form, you agree that we can call or text you at the number you provided even if you are on a federal or state do not call registry, and you also agree that these calls can be autodialed or pre-recorded.
Tell Us Your Story
Notice For: Anyone who has been exposed to Roundup Weed Killer and was subsequently diagnosed with non-Hodgkin’s Lymphoma.
Pond Lehocky Giordano is investigating claims against Roundup manufacturer Monsanto on behalf of consumers who were exposed to Roundup and later diagnosed with non-Hodgkin’s Lymphoma. For more information, please fill out the contact form.
What is Roundup?
Monsanto’s Roundup Weed Killer is the most commonly used herbicide in the world, with hundreds of millions of pounds of the chemical used every year in both professional and private settings.
What is the Roundup lawsuit?
The Roundup lawsuit came about as a result of injuries from exposure to the weed killer’s active ingredient, glyphosate, which has been found to be a carcinogen that causes non-Hodgkin’s Lymphoma (NHL) as well as various subtypes of the cancer.
In January 2024, Bayer (Monsanto’s parent company) was ordered to pay $2.25 billion to a Pennsylvania man who sued the company, alleging he developed cancer from exposure to Roundup.
A jury in the Philadelphia Court of Common Pleas agreed, finding that his non-Hodgkin’s lymphoma was the result of using Roundup for yard work at his house over a period of several years. The verdict included $250 million in compensatory damages and $2 billion in punitive damages.
INCLUDED SUBTYPES:
Mature B-cell lymphomas (about 85% to 90% of NHL cases)
Aggressive:
- Diffuse large B-cell lymphoma (DLBCL) (31%)
- Lymphoblastic lymphoma (2%)
- Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) (2%)
- High-grade B-cell lymphoma with double or triple hits (HBL)
- Primary DLBCL of the central nervous system
- Acquired immunodeficiency syndrome (AIDS)-associated lymphoma
- Mantle cell lymphoma (MCL) (can present as aggressive or indolent) (6%)
- Burkitt lymphoma (BL) (2%)
- Transformed follicular and transformed mucosa-associated lymphoid tissue lymphomas
- Primary cutaneous DLBCL, leg type
- Primary central nervous system (CNS) lymphoma
Indolent:
- Follicular lymphoma (FL) (22%)
- Chronic lymphocytic leukemia/small-cell lymphocytic lymphoma (CLL/SLL) (6%)
- Lymphoplasmacytic lymphoma (1%)
- Nodal marginal zone lymphoma (NMZL) (1%)
- Marginal zone lymphoma (MZL) (8%)
- Gastric mucosa-associated lymphoid tissue (MALT) lymphoma (5%)
- Waldenstrom macroglobulinemia (WM)
- Splenic marginal zone lymphoma (SMZL)
Mature T-cell and natural killer (NK)-cell lymphomas (about 10% to 15% of NHL cases)
Aggressive:
- Peripheral T-cell lymphoma (PTCL), not otherwise specified (6%)
- Lymphoblastic lymphoma (2%)
- Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)
- Systemic anaplastic large-cell lymphoma (ALCL) (2%)
- Hepatosplenic gamma/delta T-cell lymphoma
- Enteropathy-type intestinal T-cell lymphoma
- Angioimmunoblastic T-cell lymphoma (AITL)
- Primary cutaneous anaplastic large-cell lymphoma
Indolent:
- Cutaneous T-cell lymphoma (CTCL) (4%)
- Sezary syndrome (SS)
- Extranodal NK/T-cell lymphoma (ENK/TCL), nasal type
- Mycosis fungoides (MF)
- Adult T-cell leukemia/lymphoma
Who is at risk?
The most at-risk groups for exposure to glyphosate are landscapers, farm workers, garden center and nursery employees, and groundskeepers. Affected individuals have also successfully pursued claims due to exposure and usage that occurred at home.
Roundup settlements
Multiple jury verdicts have come back in favor of parties injured by Roundup in the amounts of $2 billion, $289 million, and $80 million.
Most recently, in January 2024, Bayer (Monsanto’s parent company) was ordered to pay $2.25 billion to a Pennsylvania man who sued the company, alleging he developed cancer from exposure to Roundup. The verdict included $250 million in compensatory damages and $2 billion in punitive damages.
What can you do?
If you or a loved one was exposed to Roundup or its active ingredient glyphosate and subsequently received a diagnosis of non-Hodgkin’s Lymphoma, or any sub-type of cancer associated with exposure, please fill out the contact form on this page for a free case evaluation.